Crossject (ALCJ.PA) Stock Price

Crossject Price

Euronext·CLOSED
1.72EUR+0.07 (+4.39 %)
Market closed

Revenue at Crossject has contracted by 2.4% per year over the past 13 years to 145,000.00 EUR. For Crossject, the net margin of -5,957.2% is down versus -265.7% a few years ago. The consensus 12-month price target for Crossject is 4.39 EUR, about 154.4% above where the stock trades today. Of 10 analysts, 9 rate the stock a buy — an overall Buy consensus. The stock trades about 23% above its 52-week low.

Crossject stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Crossject over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Crossject stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Crossject's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Crossject Stock Price History
DateCrossject Price
7/10/20261.72 EUR
7/9/20261.65 EUR
7/8/20261.63 EUR
7/7/20261.66 EUR
7/6/20261.74 EUR
7/3/20261.80 EUR
7/2/20261.79 EUR
7/1/20261.80 EUR
6/30/20261.78 EUR
6/29/20261.84 EUR
6/26/20261.83 EUR
6/25/20261.84 EUR
6/24/20261.86 EUR
6/23/20261.88 EUR
6/22/20261.88 EUR
6/19/20261.89 EUR
6/18/20261.90 EUR
6/17/20261.90 EUR
6/16/20261.90 EUR
6/15/20261.98 EUR
6/12/20261.93 EUR
6/11/20261.88 EUR
6/10/20261.85 EUR
6/9/20261.89 EUR
6/8/20261.91 EUR
6/5/20261.93 EUR
6/4/20261.99 EUR
6/3/20261.97 EUR
6/2/20262.09 EUR
6/1/20262.20 EUR
5/29/20262.25 EUR
5/28/20262.20 EUR
5/27/20262.20 EUR
5/26/20262.23 EUR
5/25/20262.34 EUR
5/22/20262.25 EUR
5/21/20262.46 EUR
5/20/20262.47 EUR
5/19/20262.17 EUR
5/18/20262.09 EUR
5/15/20261.91 EUR
5/14/20261.92 EUR
5/13/20261.92 EUR
5/12/20261.92 EUR
5/11/20261.91 EUR
5/8/20261.91 EUR
5/7/20262.04 EUR
5/6/20261.96 EUR
5/5/20261.94 EUR
5/4/20261.91 EUR
4/30/20261.90 EUR
4/29/20261.92 EUR
4/28/20261.95 EUR
4/27/20261.94 EUR
4/24/20261.95 EUR
4/23/20261.99 EUR
4/22/20262.00 EUR
4/21/20261.99 EUR
4/20/20262.00 EUR
4/17/20262.01 EUR
4/16/20261.98 EUR
4/15/20261.97 EUR
4/14/20262.08 EUR
4/13/20262.03 EUR
4/10/20261.98 EUR
4/9/20261.96 EUR
4/8/20261.95 EUR
4/7/20262.08 EUR
4/2/20262.05 EUR
3/27/20261.99 EUR
3/26/20261.98 EUR
3/25/20261.95 EUR
3/24/20262.04 EUR
3/23/20262.13 EUR
3/20/20262.05 EUR
3/19/20262.07 EUR
3/18/20262.13 EUR
3/16/20262.02 EUR
3/13/20261.96 EUR
3/12/20261.98 EUR
3/11/20261.98 EUR
3/10/20262.03 EUR
3/9/20261.99 EUR
3/6/20261.99 EUR
3/5/20262.01 EUR
2/25/20262.25 EUR
2/24/20262.22 EUR
2/23/20262.04 EUR
2/20/20261.94 EUR
2/19/20261.89 EUR
2/18/20261.93 EUR
2/17/20261.93 EUR
2/16/20261.94 EUR
2/13/20262.06 EUR
2/12/20262.06 EUR
2/11/20262.02 EUR
2/10/20262.20 EUR
2/9/20262.14 EUR
2/6/20262.04 EUR
2/5/20262.18 EUR
2/4/20261.97 EUR
2/3/20262.00 EUR
2/2/20262.03 EUR
1/30/20261.97 EUR
1/29/20261.89 EUR
1/28/20261.89 EUR
1/27/20261.97 EUR
1/26/20262.09 EUR
1/23/20262.06 EUR
1/22/20262.02 EUR
1/21/20261.98 EUR
1/20/20262.04 EUR
1/19/20262.06 EUR
1/16/20262.06 EUR
1/15/20262.03 EUR
1/14/20262.06 EUR
1/13/20262.18 EUR
1/12/20262.26 EUR
1/9/20262.31 EUR
1/8/20262.34 EUR
1/7/20262.38 EUR
1/6/20262.35 EUR
1/5/20262.39 EUR
1/2/20262.15 EUR
12/31/20252.19 EUR
12/30/20252.19 EUR
12/29/20252.20 EUR
12/24/20252.20 EUR
12/23/20252.17 EUR
12/22/20252.05 EUR
12/19/20252.08 EUR
12/18/20252.03 EUR
12/17/20252.03 EUR
12/16/20252.00 EUR
12/15/20252.08 EUR
12/12/20252.09 EUR
12/11/20252.05 EUR
12/10/20252.12 EUR
12/9/20252.15 EUR
12/8/20252.19 EUR
12/5/20252.18 EUR
12/4/20252.19 EUR
12/3/20252.11 EUR
12/2/20252.23 EUR
12/1/20252.31 EUR
11/28/20252.35 EUR
11/27/20252.36 EUR
11/26/20252.38 EUR
11/25/20252.40 EUR
11/24/20252.33 EUR
11/21/20252.34 EUR
11/20/20252.36 EUR
11/19/20252.33 EUR
11/18/20252.46 EUR
11/17/20252.58 EUR
11/14/20252.62 EUR
11/13/20252.69 EUR
11/12/20252.49 EUR
11/11/20252.50 EUR
11/10/20252.42 EUR
11/7/20252.24 EUR
11/6/20252.22 EUR
11/5/20252.28 EUR
11/4/20252.35 EUR
11/3/20252.35 EUR
10/31/20252.42 EUR
10/30/20252.55 EUR
10/29/20252.43 EUR
10/28/20252.40 EUR
10/27/20252.34 EUR
10/24/20252.43 EUR
10/23/20252.42 EUR
10/22/20252.41 EUR
10/21/20252.52 EUR
10/20/20252.45 EUR
10/17/20252.35 EUR
10/16/20252.34 EUR
10/15/20252.40 EUR
10/14/20252.47 EUR
10/13/20252.51 EUR
10/10/20252.33 EUR
10/9/20252.31 EUR
10/8/20252.48 EUR
10/7/20252.46 EUR
10/6/20252.14 EUR
10/3/20252.04 EUR
10/2/20252.02 EUR
10/1/20252.07 EUR
9/30/20251.81 EUR
9/29/20251.87 EUR
9/26/20251.72 EUR
9/25/20251.67 EUR
9/24/20251.66 EUR
9/23/20251.60 EUR
9/22/20251.70 EUR
9/19/20251.75 EUR
9/18/20251.79 EUR
9/17/20251.64 EUR
9/16/20251.60 EUR
9/15/20251.68 EUR
9/12/20251.70 EUR
9/11/20251.57 EUR
9/10/20251.49 EUR
9/9/20251.49 EUR
9/8/20251.52 EUR
9/5/20251.41 EUR
9/4/20251.41 EUR
9/3/20251.40 EUR
9/2/20251.43 EUR
9/1/20251.41 EUR
8/29/20251.47 EUR
8/28/20251.52 EUR
8/27/20251.50 EUR
8/26/20251.49 EUR
8/25/20251.57 EUR
8/22/20251.68 EUR
8/21/20251.68 EUR
8/20/20251.68 EUR
8/19/20251.72 EUR
8/18/20251.63 EUR
8/15/20251.64 EUR
8/14/20251.65 EUR
8/13/20251.56 EUR
8/12/20251.57 EUR
8/11/20251.52 EUR
8/8/20251.51 EUR
8/7/20251.46 EUR
8/6/20251.47 EUR
8/5/20251.44 EUR
8/4/20251.59 EUR
8/1/20251.58 EUR
7/31/20251.70 EUR
7/30/20251.68 EUR
7/29/20251.75 EUR
7/28/20251.74 EUR
7/25/20251.65 EUR
7/24/20251.66 EUR
7/23/20251.67 EUR
7/22/20251.61 EUR
7/21/20251.63 EUR
7/18/20251.67 EUR
7/17/20251.61 EUR
7/16/20251.61 EUR
7/15/20251.65 EUR
7/14/20251.69 EUR
Access this data via the Eulerpool API
Get Free API Key

Crossject Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2020
0.00 EUR
-10.67 M EUR
-9.84 M EUR
Jan 1, 2021
912,000.00 EUR
-11.82 M EUR
-10.81 M EUR
Jan 1, 2022
954,000.00 EUR
-13.29 M EUR
-11.16 M EUR
Jan 1, 2023
145,000.00 EUR
-11.80 M EUR
-8.64 M EUR
Jan 1, 2024
0.00 EUR
-12.96 M EUR
-12.80 M EUR
Jan 1, 2025 (e)
44.48 M EUR
9.93 M EUR
4.15 M EUR
Jan 1, 2026 (e)
48.61 M EUR
23.22 M EUR
16.14 M EUR
Jan 1, 2027 (e)
65.87 M EUR
32.08 M EUR
21.88 M EUR

Crossject Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jul 13, 2026, 12:31 PM
 
REVENUEM EUR
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM EUR
NET INCOMEM EUR
NET INCOME GROWTH%
SHARESM
20122013201420152016201720182019202020212022202320242025e2026e2027e
–––––––––––––44.0048.0065.00
––––––––––––––9.0935.42
–––––––––––––2.272.081.54
1.001.00-2.00-3.00-3.00-3.00-4.00-1.001.005.006.002.001.001.001.001.00
–-1.00-4.00-5.00-6.00-7.00-10.00-7.00-9.00-10.00-11.00-8.00-12.004.0016.0021.00
––300.0025.0020.0016.6742.86-30.0028.5711.1110.00-27.2750.00-133.33300.0031.25
2.664.416.976.977.699.3013.6820.3224.0226.8937.4937.7445.5445.5445.5445.54
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Crossject generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Crossject retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Crossject's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Crossject has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Crossject's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Crossject stock margins

The Crossject margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Crossject. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Crossject.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2020
1,885.52 %
- %
- %
Jan 1, 2021
604.28 %
-1,296.38 %
-1,184.87 %
Jan 1, 2022
724.21 %
-1,392.87 %
-1,169.50 %
Jan 1, 2023
1,885.52 %
-8,137.93 %
-5,957.24 %
Jan 1, 2024
1,885.52 %
- %
- %
Jan 1, 2025 (e)
1,885.52 %
22.31 %
9.32 %
Jan 1, 2026 (e)
1,885.52 %
47.76 %
33.19 %
Jan 1, 2027 (e)
1,885.52 %
48.70 %
33.21 %

Crossject Stock Revenue, EBIT, Earnings per Share

The Crossject earnings per share therefore indicates how much revenue Crossject has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2020
0.00 EUR
-0.44 EUR
-0.41 EUR
Jan 1, 2021
0.03 EUR
-0.44 EUR
-0.40 EUR
Jan 1, 2022
0.03 EUR
-0.35 EUR
-0.30 EUR
Jan 1, 2023
0.00 EUR
-0.31 EUR
-0.23 EUR
Jan 1, 2024
0.00 EUR
-0.28 EUR
-0.28 EUR
Jan 1, 2025 (e)
0.98 EUR
0.22 EUR
0.09 EUR
Jan 1, 2026 (e)
1.07 EUR
0.51 EUR
0.35 EUR
Jan 1, 2027 (e)
1.45 EUR
0.70 EUR
0.48 EUR

Crossject business model & stock analysis

Crossject SA is a company that specializes in the development and manufacturing of innovative drug delivery systems. The company was founded in 2006 by a team of professionals with the goal of changing the way medications are administered. Crossject's history began with the development of a unique drug delivery system called ZENEO. This system is based on a proprietary technology called "Needle Free Injection" that allows for needle-free and painless medication administration. The technology is safe, easy to use, and enables the administration of liquid medications and even solids in the form of suspensions. Crossject specializes in the application of this technology and develops products in various areas, including adrenaline for the treatment of life-threatening allergic reactions, methotrexate for the treatment of cancer, and anti-inflammatory medications for the treatment of asthma and COPD. The business model of Crossject is based on the development and commercialization of products based on the ZENEO technology. The company collaborates with a range of partners to bring its products to market, including pharmaceutical companies and other drug manufacturers. Crossject aims to sell its products worldwide and already has distribution partners in various countries around the world. Crossject is also committed to advancing the development of new products based on this technology. The company invests a significant portion of its revenue in research and development and works closely with academic institutions and other research facilities to improve its technology and products. Crossject's product offering includes a wide range of medications used for the treatment of various conditions. One example is the adrenaline injection system developed for the rapid and effective treatment of anaphylactic shocks that can occur as severe allergic reactions in people with food allergies, insect venom allergies, or drug allergies. The system does not require a needle and is therefore easy and safe to handle. Another example is the methotrexate injection for the treatment of cancer and autoimmune diseases such as rheumatoid arthritis and psoriasis. Crossject has also developed a range of products to combat asthma and chronic obstructive pulmonary disease (COPD). In 2019, the company received regulatory approval for its first commercial ZENEO product as an emergency treatment for migraines. This product is a fast-acting migraine therapy that is administered subcutaneously to quickly and effectively relieve pain and accompanying symptoms of migraines. In summary, Crossject is an innovative company specializing in the development and commercialization of drug delivery systems. The company utilizes a proprietary technology that allows for needle-free and painless medication administration and collaborates closely with partners to sell its products worldwide. Crossject continues to invest in research and development to bring new products based on its technology to market and establish itself as a leading company in its field.

Crossject SWOT Analysis

Strengths

Crossject SA has several strengths that contribute to its competitive advantage in the market. Firstly, the company possesses a unique and innovative drug delivery technology known as Zeneo®, which enables the painless and efficient administration of drugs. This technology offers significant advantages over traditional injection methods, making it a valuable asset for Crossject SA.

Additionally, Crossject SA has a strong intellectual property portfolio, including various patents and trademarks, which provide legal protection and exclusivity for their innovative drug delivery systems. This further strengthens the company's position in the market and acts as a barrier to entry for potential competitors.

Furthermore, the company has formed strategic partnerships with established pharmaceutical companies. These partnerships not only bring financial benefits to Crossject SA but also provide access to a wide range of resources, including expertise, distribution channels, and market opportunities.

Weaknesses

Despite its strengths, Crossject SA also has some weaknesses that need to be addressed. One notable weakness is the relatively limited market presence and brand recognition compared to well-established competitors. This can pose challenges in terms of market penetration and attracting a broad customer base.

Moreover, the production and commercial scale-up of their drug delivery systems may present a weakness. Maintaining a stable and cost-effective production process while meeting the increasing demand can be challenging, especially for a relatively small company like Crossject SA.

Opportunities

The market for innovative drug delivery systems is growing rapidly, driven by the rising demand for easier and less invasive administration methods. Crossject SA can capitalize on this opportunity by leveraging its unique technology and expanding its product portfolio to cater to different therapeutic areas and market segments.

Furthermore, the increasing focus on self-medication and home healthcare presents an opportunity for Crossject SA. Their painless and user-friendly drug delivery systems align well with these trends and can attract a significant customer base seeking convenient and reliable self-administration options.

Threats

Crossject SA faces threats from both existing competitors and potential new entrants in the market. Established pharmaceutical companies may try to imitate or develop similar drug delivery technologies, challenging Crossject SA's competitive advantage. Additionally, evolving regulations and reimbursement policies in the healthcare industry can impact the adoption and commercial success of the company's products.

Moreover, unexpected events such as regulatory setbacks, manufacturing disruptions, or economic downturns can significantly impact the company's operations and financial performance. Crossject SA needs to mitigate these threats through effective risk management strategies and continuous innovation.

Crossject Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Crossject historical P/E ratio, EBIT multiple, and P/S ratio

Crossject annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Crossject shares outstanding

The number of shares of Crossject was 45.54 M in 2025. This indicates how many shares Crossject is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2020
24.02 M Stocks
Jan 1, 2021
26.89 M Stocks
Jan 1, 2022
37.49 M Stocks
Jan 1, 2023
37.74 M Stocks
Jan 1, 2024
45.54 M Stocks
Jan 1, 2025 (e)
45.54 M Stocks
Jan 1, 2026 (e)
45.54 M Stocks
Jan 1, 2027 (e)
45.54 M Stocks

Current Crossject forecasts and price targets in July 2026

Analyst Price Targets 2026
Δ MOM Price Target
13.16 %
Buy90.00 % (9)
Hold10.00 % (1)
Sell0.00 % (0)
12M Price Target
4.39
Last Price
1.72
Currency
EUR
12M Return Potential
154.41 %
LTM Return
0 %

Crossject shareholder structure

% Name
22.08740%
Gemmes Venture
Gemmes Venture
0.19763%
Dynasty Asset Management S.A.
Dynasty Asset Management S.A.
0.00000%
CHART AG
CHART AG
0.00000%
Clay Asset Management SAS
Clay Asset Management SAS
0.00000%
Sunny Asset Management
Sunny Asset Management
0.00000%
Mandarine Gestion
Mandarine Gestion

Crossject Executives and Management Board

PM

Mr. Philippe Monnot

Chairman of the Supervisory Board

PA

Mr. Patrick Alexandre

(60)

Chairman of the Management Board, Co-Founder · since 2012

EN

Mr. Eric Nemeth

Independent Vice Chairman of the Supervisory Board

DC

Dr. Dan Chiche

Chief Medical Officer

HP

Mr. Henri De Parseval

Member of the Management Board

Crossject Supply Chain

Frequently asked questions about Crossject

The business model of Crossject SA revolves around the development and commercialization of innovative drug delivery systems. Crossject specializes in needle-free, self-administered emergency treatments for severe medical conditions such as anaphylactic shock and epileptic seizures. The company's proprietary technology, Zeneo®, enables the rapid and efficient delivery of drugs through the skin, ensuring quick and reliable therapy in critical situations. By combining ease of use, portability, and safety, Crossject aims to revolutionize the field of self-medication. With a focus on achieving market penetration globally, Crossject collaborates with pharmaceutical companies to expand the range of emergency treatments available through its innovative delivery platform.

All fundamentals and in-depth analysis of Crossject

Our stock analysis for Crossject stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Crossject. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Crossject Stock
Crossject Revenue→
Crossject Stock
Crossject Net Income→
Crossject Stock
Crossject P/E→
Crossject Stock
Crossject P/S→
Crossject Stock
Crossject EBIT→
Crossject Stock
Crossject Dividend→
Crossject Stock
Crossject Directors Dealings→
Crossject Stock
Crossject Stocks→
Crossject Stock
Crossject Market capitalization→
Crossject Stock
Crossject Debt→
Crossject Stock
Crossject Liabilities→
Crossject Stock
Crossject Equity→
Crossject Stock
Crossject AAQS→
Crossject Stock
Crossject Employees→
Crossject Stock
Crossject ROE→
Crossject Stock
Crossject ROA→
Crossject Stock
Crossject ROCE→
Crossject Stock
Crossject News→
Crossject Stock
Crossject Analyst Price Targets→

Health Stocks

Cryo-Cell InternationalCross Country HealthcareCryofocus Medtech (Shanghai) CoCronos GroupCryoportCRISPR TherapeuticsCryositeCrinetics PharmaceuticalsCrystalvue MedicalCresco LabsCSLCrescent BiopharmaAll Stocks A–Z →